[{"id":"15daf957-b2c4-4980-8a9a-08eb0a5becce","acronym":"RAISE","url":"https://clinicaltrials.gov/study/NCT05718323","created_at":"2023-02-08T17:00:18.337Z","updated_at":"2024-07-02T16:35:11.252Z","phase":"Phase 2","brief_title":"Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC","source_id_and_acronym":"NCT05718323 - RAISE","lead_sponsor":"ETOP IBCSG Partners Foundation","biomarkers":" SLFN11","pipe":" | ","alterations":" SLFN11 expression • SLFN11 overexpression","tags":["SLFN11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SLFN11 expression • SLFN11 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 12/20/2023","start_date":" 12/20/2023","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2024-04-05"}]